ReviewCNS drugs2012
Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?
Review in CNS drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Insulin resistance induced by olanzapine and other second-generation antipsychotics in Chinese patients with schizophrenia: a comparative review and meta-analysis.European journal of clinical pharmacology · 2019Pooled it
- The importance of incorporation of real-world evidence into the guidelines on the pharmacological treatment of schizophrenia.European archives of psychiatry and clinical neuroscience · 2025Article
- Tricyclic antipsychotics and antidepressants can inhibit α5-containing GABABritish journal of pharmacology · 2022Article
- Validation of Chinese Version of Positive and Negative Syndrome Scale-6 in Clinical Setting: A Preliminary Study.Psychiatry and clinical psychopharmacology · 2021Article
- New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263.European journal of medicinal chemistry · 2021Article
- Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics.The international journal of neuropsychopharmacology · 2017Article
- Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study.Clinical drug investigation · 2016Observational
- Experimental treatment of antipsychotic-induced movement disorders.Journal of experimental pharmacology · 2016Review
- Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China.BMC health services research · 2015Article
- Remission, response, and relapse rates in patients with acute schizophrenia treated with olanzapine monotherapy or other atypical antipsychotic monotherapy: 12-month prospective observational study.Pragmatic and observational research · 2015Article
- Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2014Article
- Clozapine: a review of clinical practice guidelines and prescribing trends.BMC psychiatry · 2014Review
- Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?Neuropsychiatric disease and treatment · 2014Article
- The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy.ClinicoEconomics and outcomes research : CEOR · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Real-world, effectiveness studies add an important new dimension to the evaluation of the benefits of individual antipsychotics. Efficacy studies have already shown the unique effectiveness of clozapine, and suggested improved outcomes for olanzapine compared with some atypical antipsychotics and a reduced tendency to produce acute and chronic movement disorders for atypical compared with typical drugs. Recent effectiveness studies largely confirm these prior observations. The CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness), CUtLASS (Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study) and SOHO (Schizophrenia Outpatient Health Outcomes) programmes confirmed the superiority of clozapine over other antipsychotics; CATIE and SOHO also confirmed olanzapine as probably the second most effective antipsychotic. Effectiveness studies have confirmed the high incidence of adverse metabolic effects with clozapine, olanzapine and (with less certainty) quetiapine but the ZODIAC (Ziprasidone Observational Study of Cardiac Outcomes) study found no excess cardiovascular events or deaths for olanzapine compared with ziprasidone. Prior observations on reduced frequency of movement disorders for second-generation versus first-generation antipsychotics were also largely (but not uniformly) supported. Overall, recent real-world studies have done much to confirm prior observations from efficacy-based randomized, controlled trials.
Indexed as
Identifiers
22668246What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.